Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03764488 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03764488 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 8 participants.
The verdict
NCT03764488, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the distribution in the central nervous system (CNS) of a microdose 99mTc-MAG3-BIIB067 co-administered with unlabeled BIIB067 (Tofersen). The secondary objective of the study is to assess the safety and tolerability of unlabeled BIIB067 co-administered with a microdose of 99mTc-MAG3-BIIB067 to healthy participants.
Interventions
- DRUG Tofersen
- DRUG 99mTc-MAG3-BIIB067
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-12-20 |
| Est. Completion | 2021-07-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03764488
The ClinicalTrials.gov registry entry for NCT03764488 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tofersen is the first listed.
NCT03764488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03764488 about?
NCT03764488 is a clinical study titled "A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults". The primary objective of the study is to evaluate the distribution in the central nervous system (CNS) of a microdose 99mTc-MAG3-BIIB067 co-administered with unlabeled BIIB067 (Tofersen). The secondary objective of the study is to assess the safety and tolerability of unlabeled BIIB067 co-administer...
What is the current status of trial NCT03764488?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-12-20. Estimated completion is 2021-07-10.
What interventions are being tested in trial NCT03764488?
The interventions under investigation include: Tofersen (DRUG), 99mTc-MAG3-BIIB067 (DRUG).
Who is sponsoring clinical trial NCT03764488?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.